Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved 10,000,000 additional shares under the 2021 Stock Incentive Plan, increasing potential equity dilution.
OCULAR THERAPEUTIX, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved 10,000,000 additional shares under the 2021 Stock Incentive Plan, increasing potential equity dilution
- Jason Robins appointed permanent CFO after serving as interim CFO since January 20, 2026
- CFO compensation increased to $535,100 salary with 45% target cash bonus
- Robins received options for 14,024 shares and RSUs covering 15,441 shares, subject to vesting
- Donald Notman remains Chief Operating Officer, supporting management continuity
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Pravin U. Dugel and Merilee Raines elected as Class III directors through the 2029 annual meeting
- Executive compensation approved advisory vote, with 116,101,559 votes for and 40,115,637 against
- Annual frequency selected for future executive compensation votes, reinforcing yearly shareholder oversight
- Incentive Plan expanded by 10,000,000 shares, increasing potential equity dilution and employee compensation capacity
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year ending December 31, 2026 with 187,152,838 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OCULAR THERAPEUTIX, INC 8-K filings
Get the next OCUL 8-K as it lands
Follow OCUL for push alerts, or ask the research agent what this filing means.